The Management of Patients With Hepatorenal Syndrome-Acute Kidney Injury: An International Perspective

Released On
August 15, 2022

Expires On
August 15, 2023

Media Type

Completion Time
105 minutes

Critical Care, Gastroenterology, Hepatology, Hospitalist, Nephrology, Pharmacy, Surgery

Kidney Disease, Pharmacology, Alcohol Dependence, HRS-AKI

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Annenberg Center for Health Sciences at Eisenhower.

Supported by an educational grant from Mallinckrodt.

Credit Available

  • Physicians — maximum of 1.75 AMA PRA Category 1 Credit(s)
  • Nurses — 1.75 contact hours
  • Pharmacists — 1.75 contact hours

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity was developed for a national audience of critical care physicians, hepatologists, nephrologists, transplant surgeons, critical care pharmacists, nurse practitioners, physician assistants, and other clinicians who care for patients with hepatorenal syndrome-acute kidney injury (HRS-AKI).

Program Overview

During these paired conversations, the faculty explore revised diagnostic criteria, emerging treatment, and coordinating effective multidisciplinary care. In addition, the faculty panel collaboratively reviews a patient case for which they share their international perspectives on the nonpharmacological and pharmacological treatment of patients with HRS-AKI.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Implement American Association for the Study of Liver Disease (AASLD) criteria in the diagnosis of patients with HRS-AKI
  • Discuss the role of nonpharmacologic and pharmacologic therapies for the treatment of HRS-AKI according to current AASLD and Society of Critical Care Medicine (SCCM) guideline recommendations
  • Compare the clinical pharmacology of currently available and emerging vasoconstrictors for HRS-AKI
  • Describe the safety and efficacy of vasoconstrictor options for the treatment of patients with HRS-AKI, based on clinical trials and real-world, international experience
  • Compare treatment approaches to HRS-AKI recommended in AASLD and SCCM guidelines
  • Apply current guideline recommendations as a multidisciplinary care team in treating patients with HRS-AKI



Paolo Angeli, MD, PhD

University of Padova
Padova, Italy


Amanda Chaney, DNP, APRN

Senior Director of Advanced Practice Services
Cleveland Clinic
Florida Region
Weston, Florida


Kevin Moore, MB.BS, PhD

Institute of Liver and Digestive Health
University College
London, United Kingdom


Mitra K. Nadim, MD

Director, USC Hypertension Center
Keck Medicine of USC
Los Angeles, California


Rahul Nanchal, MD

Division of Pulmonary and Critical Care Medicine
Medical College of Wisconsin
Milwaukee, Wisconsin


Ram Subramanian, MD, MBA

Director of Liver Critical Care Services
Emory University School of Medicine
Atlanta, Georgia

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program # 0797-0000-22-009-H01-P.

This program is designated for up to 1.75 contact hours (0.175 CEUs) of continuing pharmacy education credit.

Annenberg Center for Health Sciences is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1.75 contact hours may be earned for successful completion of this activity.

Disclosures of Conflicts of Interest

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Paolo Angeli, MD, PhD
  • Advisory Board: BioVie, Gilead, Ferring
  • Research Support: Gilead
  • Speakers Bureau: CSL Behring, Grifols, Kedrion
Amanda Chaney, DNP, APRN
  • Author: Springer Publishing
Kevin Moore, MBBS, PhD
  • Consultant: Mallinckrodt Pharmaceuticals
Mitra K. Nadim, MD
  • Consultant: Mallinckrodt Pharmaceuticals
Ram Subramanian, MD, MBA
  • Consultant: Mallinckrodt Pharmaceuticals

Rahul Nanchal, MD, has no relevant financial relationships to disclose.

The faculty for this activity have disclosed that there will be discussion about the use of products for non-FDA approved applications.

Additional content planners
The following have no significant relationship to disclose:
Ishaq Lat, PharmD (Medical Writer)
Kam Newman, MD (Peer Reviewer)
Heather Jimenez FNP-C (Nurse Reviewer)

Annenberg Center for Health Sciences
All staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

Instructions for Participation and Credit

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

The faculty for this activity have disclosed that there will be discussion about the use of products for non-FDA approved applications.


The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Contact Information

For help or questions about this activity please contact Continuing Education: